Egholm Michael 4
4 · STANDARD BIOTOOLS INC. · Filed Apr 8, 2026
Research Summary
AI-generated summary of this filing
Standard BioTools (LAB) CEO Michael Egholm Receives RSUs, Exercises Options
What Happened
Michael Egholm, President & CEO and a director of Standard BioTools (LAB), received equity awards and completed a conversion/exercise of derivative awards. On 2026-03-20 he was granted 1,042,373 shares (RSUs) and 2,345,340 derivative awards (reported at $0.00). On 2026-04-06 he exercised/converted 196,513 derivative shares at $0.00. To satisfy tax withholding obligations tied to vested RSUs, 95,014 shares were withheld/disposed on 2026-04-06 at $0.91 per share for a reported withholding amount of $86,273.
Key Details
- Transaction dates: Grants on 2026-03-20; exercise/conversion and tax withholding on 2026-04-06; Form 4 filed 2026-04-08.
- Reported prices/values: Grants and exercise/conversion at $0.00; tax-withheld shares recorded at $0.91/share for $86,273.
- Shares owned after transaction: Not specified in the provided filing details.
- Notable footnotes:
- RSUs vest over four years with 1/16 vesting on May 20, 2026 and remaining RSUs vesting in equal quarterly installments thereafter (F1, F4).
- The withheld 95,014 shares satisfied tax obligations arising from vesting of RSUs granted April 4, 2022 (original grant reported on Form 4 filed April 6, 2022) (F2, F5).
- The derivative award becomes exercisable as to 1/16 of the underlying shares on May 20, 2026, with remaining vesting in equal quarterly installments thereafter (F3).
- Filing timeliness: Grants dated March 20 were reported on April 8 (appears late relative to the usual two-business-day Form 4 deadline); the April 6 conversion/withholding was reported on April 8 (within two business days).
Context
- This filing reflects awards and standard post-vesting mechanics (conversion/exercise and shares withheld to cover taxes), not an open-market sale or purchase. The conversion/exercise at $0.00 reflects exercising/vesting of previously granted derivative awards/RSUs rather than a cash purchase. Withheld shares to cover taxes are routine and do not by themselves indicate a change in the insider’s market view.
Insider Transaction Report
Form 4
Egholm Michael
DirectorPresident & CEO
Transactions
- Award
Common Stock
[F1]2026-03-20+1,042,373→ 6,594,083 total - Exercise/Conversion
Common Stock
2026-04-06+196,513→ 6,790,596 total - Tax Payment
Common Stock
[F2]2026-04-06$0.91/sh−95,014$86,273→ 6,695,582 total - Award
Stock Option (Right to buy)
[F3]2026-03-20+2,345,340→ 2,345,340 totalExercise: $0.98Exp: 2036-03-20→ Common Stock (2,345,340 underlying) - Exercise/Conversion
Restricted Stock Units
[F4][F5]2026-04-06−196,513→ 0 total→ Common Stock (196,513 underlying)
Footnotes (5)
- [F1]Represents restricted stock units ("RSUs") that vest over four years, with 1/16 of the RSUs vesting on May 20, 2026 and the remaining RSUs vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
- [F2]The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of RSUs granted to the reporting person on April 4, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 6, 2022.
- [F3]The Option becomes exercisable as to 1/16th of the underlying shares on May 20, 2026, with the remaining shares vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
- [F4]Each RSU represents the contingent right to receive one share of the Issuer's common stock.
- [F5]On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.
Signature
/s/ Michael Egholm by Hanjoon Alex Kim, Attorney-in-Fact|2026-04-08